Helping people with kidney disease get SGLT2 inhibitor medicines in Thailand, Fiji and Samoa
Studies ways to help adults with kidney disease get SGLT2 inhibitor medicines.
Plain-language title generated from the registry record
Registry title: Trial Without Borders IMPLEMENT-CKD: IMPLEMENTation of Evidence-Based SGLT2i to Reduce Global Burden of Cardiovascular and Chronic Kidney Disease
Key facts
- Where
- Suva, FijiSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic kidney disease or type 2 diabetes. It aims to make SGLT2 inhibitor medicines easier to get in regular care.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Chronic kidney disease with eGFR above 20 mL/min/1.73m², or type 2 diabetes.
- Biomarker or test result
- eGFR above 20 mL/min/1.73m² for people with chronic kidney disease.
Read by machine on 9 November 2026.
Where in Fiji
- Ministry of Health, FijiSuva, FijiNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The University of Queensland
- Trial code
- NCT07854808
- Record updated
- 2 October 2026
- Original description
Chronic kidney disease (CKD) affects millions, especially in low- and middle-income countries, where many die early due to lack of treatment. One group of medicines, called SGLT2 inhibitors (SGLT2i), have been shown to slow down kidney damage and reduce the risk of heart-related deaths. The IMPLEMENT-CKD project will work with communities in Thailand, Fiji and Samoa to make it easier for people with CKD or type 2 diabetes to get these life-saving medicines as part of their regular care.Read full original descriptionShow less
Trial Without Borders IMPLEMENT-CKD: IMPLEMENTation of Evidence-Based SGLT2i to Reduce Global Burden of Cardiovascular and Chronic Kidney Disease
Chronic kidney disease (CKD) affects millions, especially in low- and middle-income countries, where many die early due to lack of treatment. One group of medicines, called SGLT2 inhibitors (SGLT2i), have been shown to slow down kidney damage and reduce the risk of heart-related deaths. The IMPLEMENT-CKD project will work with communities in Thailand, Fiji and Samoa to make it easier for people with CKD or type 2 diabetes to get these life-saving medicines as part of their regular care.
Inclusion: People ≥ 18 years of age with one or more of the following:; chronic kidney disease (CKD) with eGFR > 20 mL/min/1.73m²; type 2 diabetes mellitus (T2DM).
Exclusion: Nil.